Table 3. Treatment strategies for newly-diagnosed follicular lymphoma.

Stage	stratification	Category I recommendations	Category II recommendations
ISRT, involved-site radiotherapy; *, indications for treatment: 1) candidate for clinical trial; 2) symptoms; 3) threatened end-organ function; 4) cytopenia secondary to lymphoma; 5) bulky disease; 6) steady or rapid progression.
I−II	Stage I or contiguous stage II	ISRT (Level 2A evidence)	Observation or ISRT + rituximab/obinutuzumab ± chemotherapy or rituximab/obinutuzumab ± chemotherapy + ISRT (ISRT is considered for selected patients) (Level 2A evidence)
	Non-contiguous stage II	Rituximab/obinutuzumab ± chemotherapy + ISRT (Level 2A evidence)	Observation (Level 2A evidence)
III−IV	Without indication*	Observation (Level 1A evidence)	Clinical trial (Level 2A evidence)
	With indication*	Chemotherapy ± rituximab/obinutuzumab (Level 2A evidence)	Clinical trial Palliative ISRT (Level 2A evidence)